372 related articles for article (PubMed ID: 31973111)
1. Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection.
Kura B; Kalocayova B; Devaux Y; Bartekova M
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973111
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease.
Moghaddam AS; Afshari JT; Esmaeili SA; Saburi E; Joneidi Z; Momtazi-Borojeni AA
Atherosclerosis; 2019 Jun; 285():1-9. PubMed ID: 30939341
[TBL] [Abstract][Full Text] [Related]
3. Interactions between microRNAs and long non-coding RNAs in cardiac development and repair.
Rotini A; Martínez-Sarrà E; Pozzo E; Sampaolesi M
Pharmacol Res; 2018 Jan; 127():58-66. PubMed ID: 28629929
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy.
Lai L; Chen J; Wang N; Zhu G; Duan X; Ling F
Life Sci; 2017 Jan; 169():69-75. PubMed ID: 27633839
[TBL] [Abstract][Full Text] [Related]
5. Circadian MicroRNAs in Cardioprotection.
Oyama Y; Bartman CM; Gile J; Eckle T
Curr Pharm Des; 2017; 23(25):3723-3730. PubMed ID: 28699517
[TBL] [Abstract][Full Text] [Related]
6. β-arrestin-biased agonism of β-adrenergic receptor regulates Dicer-mediated microRNA maturation to promote cardioprotective signaling.
Teoh JP; Bayoumi AS; Aonuma T; Xu Y; Johnson JA; Su H; Weintraub NL; Tang Y; Kim IM
J Mol Cell Cardiol; 2018 May; 118():225-236. PubMed ID: 29627294
[TBL] [Abstract][Full Text] [Related]
7. A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes.
Bayoumi AS; Park KM; Wang Y; Teoh JP; Aonuma T; Tang Y; Su H; Weintraub NL; Kim IM
J Mol Cell Cardiol; 2018 Jan; 114():72-82. PubMed ID: 29122578
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?
Fichtlscherer S; Zeiher AM; Dimmeler S
Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2383-90. PubMed ID: 22011751
[TBL] [Abstract][Full Text] [Related]
9. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
Ky B; Carver JR
Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
[TBL] [Abstract][Full Text] [Related]
10. Small Molecules with Big Impacts on Cardiovascular Diseases.
Mirzadeh Azad F; Arabian M; Maleki M; Malakootian M
Biochem Genet; 2020 Jun; 58(3):359-383. PubMed ID: 31997044
[TBL] [Abstract][Full Text] [Related]
11. Clinical cardioprotection and the value of conditioning responses.
Peart JN; Headrick JP
Am J Physiol Heart Circ Physiol; 2009 Jun; 296(6):H1705-20. PubMed ID: 19363132
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs Mediate Beneficial Effects of Exercise in Heart.
Bei Y; Tao L; Cretoiu D; Cretoiu SM; Xiao J
Adv Exp Med Biol; 2017; 1000():261-280. PubMed ID: 29098626
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-320 involves in the cardioprotective effect of insulin against myocardial ischemia by targeting survivin.
Yang N; Wu L; Zhao Y; Zou N; Liu C
Cell Biochem Funct; 2018 Apr; 36(3):166-171. PubMed ID: 29521436
[TBL] [Abstract][Full Text] [Related]
14. Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets.
Zorio E; Medina P; Rueda J; Millán JM; Arnau MA; Beneyto M; Marín F; Gimeno JR; Osca J; Salvador A; España F; Estellés A
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):82-90. PubMed ID: 19149547
[TBL] [Abstract][Full Text] [Related]
15. Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics.
Gangwar RS; Rajagopalan S; Natarajan R; Deiuliis JA
Am J Hypertens; 2018 Jan; 31(2):150-165. PubMed ID: 29186297
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in cardiovascular ageing.
Seeger T; Boon RA
J Physiol; 2016 Apr; 594(8):2085-94. PubMed ID: 26040259
[TBL] [Abstract][Full Text] [Related]
17. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.
Zhou SS; Jin JP; Wang JQ; Zhang ZG; Freedman JH; Zheng Y; Cai L
Acta Pharmacol Sin; 2018 Jul; 39(7):1073-1084. PubMed ID: 29877320
[TBL] [Abstract][Full Text] [Related]
18. A Review of the Dual Role of MicroRNA-21 in Cardiovascular Diseases: Risk Factor or a Potential Therapeutic Target.
Jafari-Nozad AM; Rostami N; Esmaeili M; Vahdati H; Hosseini S; Farkhondeh T; Samarghandian S
Curr Mol Pharmacol; 2024 Jan; ():. PubMed ID: 38369766
[TBL] [Abstract][Full Text] [Related]
19. Protecting the heart in cancer therapy.
Finet JE; Tang WHW
F1000Res; 2018; 7():. PubMed ID: 30345014
[TBL] [Abstract][Full Text] [Related]
20. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity.
Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
